AU2010270971B2 - Methods for treating or preventing fatigue - Google Patents

Methods for treating or preventing fatigue Download PDF

Info

Publication number
AU2010270971B2
AU2010270971B2 AU2010270971A AU2010270971A AU2010270971B2 AU 2010270971 B2 AU2010270971 B2 AU 2010270971B2 AU 2010270971 A AU2010270971 A AU 2010270971A AU 2010270971 A AU2010270971 A AU 2010270971A AU 2010270971 B2 AU2010270971 B2 AU 2010270971B2
Authority
AU
Australia
Prior art keywords
compound
carbon atoms
fatigue
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010270971A
Other languages
English (en)
Other versions
AU2010270971A1 (en
Inventor
Gary Bream
Stephen E. Butts
Moise A. Khayrallah
Susan Marie Melnick
Duncan Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of AU2010270971A1 publication Critical patent/AU2010270971A1/en
Application granted granted Critical
Publication of AU2010270971B2 publication Critical patent/AU2010270971B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010270971A 2009-06-22 2010-06-21 Methods for treating or preventing fatigue Active AU2010270971B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21908209P 2009-06-22 2009-06-22
US61/219,082 2009-06-22
PCT/US2010/039313 WO2011005473A2 (en) 2009-06-22 2010-06-21 Methods for treating or preventing fatigue

Publications (2)

Publication Number Publication Date
AU2010270971A1 AU2010270971A1 (en) 2012-01-19
AU2010270971B2 true AU2010270971B2 (en) 2015-08-20

Family

ID=43429751

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010270971A Active AU2010270971B2 (en) 2009-06-22 2010-06-21 Methods for treating or preventing fatigue

Country Status (13)

Country Link
US (5) US8741950B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2445490B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP6095366B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR20120098578A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN102481274A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2010270971B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI1015233A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2765463C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2012DN00624A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2012000034A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2567801C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI453014B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2011005473A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5024635B2 (ja) 2005-06-08 2012-09-12 エスケー バイオファーマスティカルズ カンパニー リミテッド 睡眠覚醒障害の治療
IN2012DN00624A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2009-06-22 2015-06-12 Sk Biopharmaceuticals Co Ltd
US8927602B2 (en) * 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
PL2496228T3 (pl) 2009-11-06 2014-06-30 Sk Biopharmaceuticals Co Ltd Sposoby leczenia zespołu nadpobudliwości psychoruchowej/deficytu uwagi
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
AU2012359081B2 (en) 2011-12-21 2015-09-17 Innobioscience, Llc Combination therapy with interferon and andrographolides for multiple sclerosis
TWI684450B (zh) 2013-03-13 2020-02-11 南韓商愛思開生物製藥股份有限公司 猝倒症之治療
CN105848650A (zh) * 2013-07-12 2016-08-10 爵士制药国际Iii有限公司 促进吸烟停止
CN105873576B (zh) 2013-07-18 2019-07-19 爵士制药国际Iii有限公司 治疗肥胖
PL3065751T3 (pl) * 2013-11-08 2020-07-13 Legacy Healthcare Ltd Sposób leczenia raka i chorób współistniejących
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
JP7219213B2 (ja) 2016-09-06 2023-02-07 ジャズ ファーマスティカルズ アイルランド リミテッド （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの溶媒和物フォーム
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
ES2964943T3 (es) 2016-10-06 2024-04-10 Axsome Malta Ltd Compuestos de carbamoilfenilalaninol para uso médico
CN110139905B (zh) * 2016-12-30 2021-09-28 株式会社东进世美肯 涂层组合物及由此制备的薄膜
KR102726728B1 (ko) 2017-06-02 2024-11-05 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
CN111094238B (zh) 2017-07-31 2023-06-09 杰资制药爱尔兰有限公司 氨基甲酰基苯丙氨醇类似物及其用途
JP7428480B2 (ja) * 2019-06-06 2024-02-06 雪印メグミルク株式会社 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
KR20240101826A (ko) * 2021-11-16 2024-07-02 액섬 몰타 엘티디. 인지 장애를 치료하기 위한 방법 및 조성물
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015526A1 (en) * 1996-10-10 1998-04-16 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
US6140532A (en) * 1995-04-10 2000-10-31 Sk Corporation O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same
WO2006133393A1 (en) * 2005-06-08 2006-12-14 Sk Holdings Co., Ltd. Treatment of sleep-wake disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA943862B (en) 1993-06-10 1995-12-04 Lilly Co Eli Method of preventing emesis and treating sexual dysfunction using tetrahydrobenz[cd] indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
WO1998015626A2 (en) 1996-10-08 1998-04-16 Institute Of Child Health Mutant ciita molecule and uses thereof
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US20040229951A1 (en) 2003-05-15 2004-11-18 Arthur Vanmoor Method of treating fatigue by enhancing the effectiveness of the human immune system
RU2267319C2 (ru) * 2003-07-15 2006-01-10 Общество с ограниченной ответственностью "Интер-Кэр" Фармацевтическая композиция и способ лечения синдрома хронической усталости с ее использованием
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
CA2587481A1 (en) 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
DE602006012670D1 (de) 2005-06-22 2010-04-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
JP5094720B2 (ja) 2005-07-26 2012-12-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ サブスタンス関連障害を処置する方法
KR20090082213A (ko) 2006-10-13 2009-07-29 얀센 파마슈티카 엔.브이. 페닐알킬아미노 카바메이트 조성물
IN2012DN00624A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2009-06-22 2015-06-12 Sk Biopharmaceuticals Co Ltd
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
PL2496228T3 (pl) 2009-11-06 2014-06-30 Sk Biopharmaceuticals Co Ltd Sposoby leczenia zespołu nadpobudliwości psychoruchowej/deficytu uwagi
US8927602B2 (en) 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
TWI684450B (zh) * 2013-03-13 2020-02-11 南韓商愛思開生物製藥股份有限公司 猝倒症之治療
JP6215740B2 (ja) * 2014-03-14 2017-10-18 本田技研工業株式会社 部品の締結構造

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140532A (en) * 1995-04-10 2000-10-31 Sk Corporation O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same
WO1998015526A1 (en) * 1996-10-10 1998-04-16 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
WO2006133393A1 (en) * 2005-06-08 2006-12-14 Sk Holdings Co., Ltd. Treatment of sleep-wake disorders

Also Published As

Publication number Publication date
KR20190105675A (ko) 2019-09-17
US20180263950A1 (en) 2018-09-20
CN102481274A (zh) 2012-05-30
EP2445490A2 (en) 2012-05-02
US20200061017A1 (en) 2020-02-27
WO2011005473A9 (en) 2011-05-12
US20120142769A1 (en) 2012-06-07
CA2765463A1 (en) 2011-01-13
MX2012000034A (es) 2012-02-21
US9999609B2 (en) 2018-06-19
TW201105320A (en) 2011-02-16
US20140243406A1 (en) 2014-08-28
RU2567801C2 (ru) 2015-11-10
WO2011005473A2 (en) 2011-01-13
US20170000756A1 (en) 2017-01-05
US8741950B2 (en) 2014-06-03
CA2765463C (en) 2018-10-09
KR20170086710A (ko) 2017-07-26
IN2012DN00624A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-06-12
JP2012530779A (ja) 2012-12-06
EP2445490B1 (en) 2023-02-08
JP2018188450A (ja) 2018-11-29
KR102021075B1 (ko) 2019-11-04
KR102173587B1 (ko) 2020-11-04
KR20120098578A (ko) 2012-09-05
CN106727486A (zh) 2017-05-31
RU2012101947A (ru) 2013-07-27
US9464041B2 (en) 2016-10-11
EP2445490A4 (en) 2019-10-23
JP6368285B2 (ja) 2018-08-01
TWI453014B (zh) 2014-09-21
JP2015214564A (ja) 2015-12-03
JP6095366B2 (ja) 2017-03-15
BRPI1015233A2 (pt) 2018-02-20
US10507192B2 (en) 2019-12-17
AU2010270971A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
US10507192B2 (en) Methods for treating or preventing fatigue using O-carbamoyl-phenylalaninol compounds
ES2564935T3 (es) Derivados de quinazolinona 5-sustituidos como agentes anti-cancerosos
EP2965756B1 (en) Selective ep4 receptor antagonistic substance for treatment of cancer
US9248098B2 (en) Treating or preventing pain using spicamycin derivatives
US20160279160A1 (en) Compositions comprising spicamycin derivatives and methods of use thereof
HK1234314A1 (en) Methods for treating or preventing fatigue
HK1171657A (en) Methods for treating or preventing fatigue
US20220125844A1 (en) Opioid antagonists for use in patients using chimeric antigen receptor t and natural killer (nk) cell therapy
HK40003061B (en) Selective ep4 receptor antagonistic substance for treatment of cancer
HK1214763B (en) Selective ep4 receptor antagonistic substance for treatment of cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)